Perioperative genetic testing and time to surgery in patients with breast cancer

Wu, Vincent; Chichura, Anna M.; Dickard, Jennifer; Turner, Christine; Al-Hilli, Zahraa

doi:10.1016/j.surg.2023.08.043

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings advocate for the integration of genetic testing into the standard of care for breast cancer patients, facilitating risk stratification, informed decision-making regarding surveillance and preventive measures, and the optimization of therapeutic approaches based on genetic profiles. Furthermore, these results contribute to the growing body of knowledge regarding the genetic landscape of breast cancer, suggesting the need for ongoing research to uncover the full spectrum of genetic factors that contribute to breast cancer risk and progression [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

Oncotype DX in Breast Cancer Management: Insights and Outcomes From the United Arab Emirates

Ameri,

Shanbhag,

Bin Sumaida

et al. 2024

Cureus

View full text Add to dashboard Cite

Introduction Breast cancer remains the most significant cancer affecting women worldwide, with an increasing incidence, especially in developing regions. The introduction of genomic tests like Oncotype DX has revolutionized personalized treatment, allowing for more tailored approaches to therapy. This study focuses on the United Arab Emirates (UAE), where breast cancer is the leading cause of cancer-related deaths among women, aiming to assess the predictive accuracy of the Oncotype DX test in categorizing patients based on recurrence risk. Materials and methods A retrospective cohort study was conducted on 95 breast cancer patients diagnosed at Tawam Hospital between 2013 and 2017 who underwent Oncotype DX testing. Data on patient demographics, tumor characteristics, treatment details, and Oncotype DX scores were collected. Survival analysis was performed using the Kaplan-Meier method, with the chi-square goodness of fit test assessing the model’s adequacy. Results The cohort’s age range was 27-71 years, with a mean age of 50, indicating a significant concentration of cases in the early post-menopausal period. The Oncotype DX analysis classified 55 patients (57.9%) as low risk, 29 (30.5%) as medium risk, and 11 (11.6%) as high risk of recurrence. The majority, 73 patients (76.8%), did not receive chemotherapy, highlighting the test’s impact on treatment decisions. The survival analysis revealed no statistically significant difference in recurrence rates across the Oncotype DX risk categories (p = 0.268231). Conclusion The Oncotype DX test provides a valuable genomic approach to categorizing breast cancer patients by recurrence risk in the UAE. While the test influences treatment decisions, particularly the use of chemotherapy, this study did not find a significant correlation between Oncotype DX risk categories and actual recurrence events. These findings underscore the need for further research to optimize the use of genomic testing in the UAE’s diverse patient population and enhance personalized treatment strategies in breast cancer management.

show abstract

Section: Discussionmentioning

confidence: 99%